Trial
NCT03366766
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Collaborators
Bristol-Myers Squibb
Condition
Non-Squamous Non-Small Cell Lung Carcinoma
Intervention
Nivolumab
Why stopped
slow accrual and lack of additional funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-20